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Abstract
Background: Exposure assessment has shifted from pollutant monitoring in air, soil, and water
toward personal exposure measurements and biomonitoring. This trend along with the paucity of
health effect data for many of the pollutants studied raise ethical and scientific challenges for
reporting results to study participants.
Methods: We interviewed 26 individuals involved in biomonitoring studies, including academic
scientists, scientists from environmental advocacy organizations, IRB officials, and study
participants; observed meetings where stakeholders discussed these issues; and reviewed the
relevant literature to assess emerging ethical, scientific, and policy debates about personal exposure
assessment and biomonitoring, including public demand for information on the human health effects
of chemical body burdens.
Results: We identify three frameworks for report-back in personal exposure studies: clinical
ethics; community-based participatory research; and citizen science 'data judo.' The first approach
emphasizes reporting results only when the health significance of exposures is known, while the
latter two represent new communication strategies where study participants play a role in
interpreting, disseminating, and leveraging results to promote community health. We identify five
critical areas to consider in planning future biomonitoring studies.
Conclusion: Public deliberation about communication in personal exposure assessment research
suggests that new forms of community-based research ethics and participatory scientific practice
are emerging.
Background
Tired of government inaction toward community con-
cerns about pollution from refineries in her neighbor-
hood, Ethel Dotson, a 53-year resident of Richmond,
California, decided it was time to up the ante: armed with
10 vials of her own blood, she and several other residents
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gathered in front of California's Hazardous Materials Lab-
oratory and demanded that officials test their blood for
dioxin and other contaminants. "I have a right to know
what's in my body," she argued [1]. Dotson's demand to
document 'chemical trespass' [2] in her body reveals the
scientific promise as well as policy and ethical challenges
of the rapidly expanding field of chemical biomonitoring.
Biomonitoring, or body burden research, involves the
assessment of the presence and concentration of chemi-
cals in humans by measuring the parent chemical, its
metabolite, or reaction product in human blood, urine,
breast milk, saliva, breath, hair, or other tissue [3]. Bio-
monitoring as a tool for human exposure assessment has
been used for decades, particularly in occupational set-
tings [4,5], and, perhaps most commonly, for lead, start-
ing in the late 1800s [6]. Later, biomonitoring studies by
the Centers for Disease Control (CDC) during 1976–1980
documented significant declines in blood lead levels cor-
responding to the decline of lead in gasoline [7]. Popula-
tion-based biomonitoring of blood lead levels in children
was adopted to track the effectiveness of poisoning pre-
vention strategies and to detect cases where exposures
from homes contaminated with lead paint need to be
remediated [8].
As public health increasingly targets the environmental
determinants of chronic diseases, biomonitoring is fast
becoming a key strategy for providing a scientific basis for
prevention via exposure reduction and motivating action.
These efforts rest on newly developed analytical methods
that detect ever lower concentrations of an increasing
number of chemicals for which animal and cell studies
show troubling biological effects, but human exposure
levels, exposure sources, health effects, and exposure
reduction strategies are not yet well understood. As stated
in the 2006 National Academy of Sciences' report Human
Biomonitoring for Environmental Chemicals, although bio-
monitoring has advanced significantly, researchers, regu-
lators, and decision-makers face new challenges about
how to interpret, report, and act on results that only par-
tially elucidate links between environmental chemicals
and health [9]. This paper heeds NAS's call for additional
research that elucidates new approaches for addressing
the scientific and ethical challenges of biomonitoring
results communication in the United States. Although we
focus on exposure biomonitoring throughout, parallel
issues are raised by other personal exposure assessment
methods, such as dust and air samples taken from an indi-
vidual's home.
Exposure assessment has always been one of most meth-
odologically challenging aspects of environmental health
science and environmental epidemiology. The last ten
years have seen significant advances that allow scientists
to assess and characterize chemical body burdens and
potential health risks, including those that may have more
than one route of entry into the body (e.g. inhalation,
ingestion, and dermal) [10,11]. Biomonitoring tech-
niques can be divided into three basic categories: biomar-
kers of exposure, effect and susceptibility [12,13].
Previously restricted to logistically challenging and costly
academic research and occupational cohort studies, bio-
monitoring techniques, particularly for exposure, have
become more widely available, practical, and less expen-
sive. This has resulted in the proliferation of biomonitor-
ing studies among scientists in academia, state and federal
agencies, environmental advocacy organizations, and
non-profit research institutes.
The visibility and policy impacts of this new wave of bio-
monitoring have been profound. Scientific journals and
the media have reported on a flood of studies, including
flame retardants in breast milk [14,15], pesticides in
umbilical cord blood [16], and endocrine disrupting com-
pounds (EDCs) in household air and dust and house-
holders' blood and urine [11]. In 1999, the federal
government began systematically tracking personal expo-
sures in a representative sample of the US population
[17]. When results were released in April 2001, Richard
Jackson, then-director of CDC's National Center for Envi-
ronmental Health, predicted that biomonitoring "could
be revolutionary for environmental health research in the
United States" [18], as these new exposure assessment
methods and the data they provide are much-needed to
advance environmental epidemiology, environmental
health policy, and regulation. Recent CDC biomonitoring
results have highlighted the effectiveness of antismoking
efforts, including banning smoking in public places, and
have focused attention on surprising exposures of women
of reproductive age to hormonally active chemicals from
consumer products [19]. CDC has continued issuing body
burden reports every two years, expanding the number of
chemicals tested, and is encouraging states to develop
their own biomonitoring programs [7,19,20]. In Septem-
ber 2006, California became the first state to do so [21].
Although biomonitoring is a direct indicator of human
exposure to certain compounds and their metabolites,
this technique cannot generally be used to easily identify
their sources. As one biomonitoring study participant
states: "None of these chemicals come with a return
address." Moreover, these techniques are rarely able to
predict health outcomes or even sub-clinical effects in
humans. As biomonitoring procedures become less
costly, researchers have expanded the array of chemicals
being studied, yet many of these substances lack toxico-
logical or epidemiological evidence regarding their poten-
tial health effects [22] and regulatory benchmarks forEnvironmental Health 2009, 8:6 http://www.ehjournal.net/content/8/1/6
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comparison [23]. This makes it imperative to address
some specific ethical challenges of biomonitoring.
We first review the evolution of exposure assessment sci-
ence and the emerging ethical issues associated with the
proliferation of biomonitoring techniques and the com-
munication of results. We then describe our methods for
recruiting and interviewing individuals involved in bio-
monitoring research about their opinions and practices.
Our results identify three approaches used by academic
scientists and environmental organizations to communi-
cate information about the effects of chemical exposures
on health and to leverage regulatory and policy change: 1)
clinical ethics; 2) community-based participatory
research; and 3) citizen science 'data judo.' The first is bio-
medically driven, while the latter two emphasize preven-
tion research and advocacy. Our results also reveal the
ethical and administrative issues faced by scientists when
considering whether and how to report individual expo-
sure information to study participants. We then report on
guidance offered by government publications, profes-
sional association "best practice" guidelines, and journal
articles concerning individual results communication and
make recommendations based on our interviews with
researchers currently collecting and reporting individual
exposure data. We conclude with some of the ethical con-
siderations for future work in this area.
Evolution of Exposure Assessment Science and Emerging 
Ethical Issues
There is little guidance for scientists and academic-com-
munity research collaboratives that want to report indi-
vidual and community-level exposure data to study
participants. One of the first fields of public health to
grapple with the issue of biomonitoring and individual
report-back was occupational health. In the 1960s, testing
of blood, urine, and other tissues was a well-established
practice for occupational health surveillance and research,
although only a small portion of the many chemicals
common in work environments were consistently exam-
ined, in part due to limitations in chemical analytic capac-
ity [19,24]. Occupational health researchers typically
conduct retrospective occupational cohort studies, in
which morbidity and mortality records for a population
of individuals who worked in a particular environment
are analyzed to determine associations between exposures
and adverse health outcomes. Historically, cohort mem-
bers were not notified about individual findings, even
though this information could have served as a basis for
efforts to reduce exposures or conduct health screenings to
potentially reduce morbidity and mortality risks. How-
ever, in a speech delivered to NIOSH in 1982, bioethicist
John Fletcher called on epidemiologists to "join other bio-
medical scientists who have the obligation to notify study
subjects" [25]. The notification of individuals in a cohort
study is now standard [25-27], and is explicated in
OSHA's Hazard Communication Standards of 1983 and
1987 [26,27].
Technical developments now enable environmental
health researchers to widen their gaze from a previous
focus on pollutants in occupational settings and contam-
inated environmental media such as air or water toward
contaminants in human tissues. Moreover, smaller-scale
biomonitoring studies conducted by environmental
advocacy organizations have been effective vehicles for
promoting precautionary approaches to chemical regula-
tion [7,17,28]. For example, policymakers in Europe and
California used data from breast milk monitoring to
encourage a recent phase-out of certain PBDEs (polybro-
minated diphenyl ethers), flame retardants ubiquitously
used in electronic equipment, furniture, and other prod-
ucts [29]. This strategy of advocacy biomonitoring has
been replicated by numerous organizations in the U.S.
and abroad to address other potential hazards, such as
parabens in cosmetics and exposures from PFOA (per-
fluorooctanoate), which is used to manufacture Teflon
[30].
New ethical dilemmas have emerged regarding the report-
ing of exposure data, especially since information about
health outcomes and dose-response relationships is
uncertain or not available [31,32]. Indeed, nearly 85,000
chemicals are currently registered for commercial use, yet
barely ten percent have undergone basic toxicity testing,
and these do not include assessments of carcinogenic,
developmental, reproductive, neurological, immunologi-
cal, or endocrine effects [22]. Quantifying chemicals in
biological samples inherently precedes understanding
their effects, because exposure measurements are needed
before we can evaluate links to health [4,33]. Thus, scien-
tists are confronted by the question of whether an ethical
obligation exists to notify participants of their exposure
results, or to withhold this information if it does not offer
clear insights on health effects or the sources and path-
ways of exposure. Moreover, the implications of results
for individuals and communities are further complicated
by interactions of environmental exposures with individ-
ual and population differences in genetics, nutrition,
health status, health-related behaviors, and lifetime expo-
sures to other contaminants [34].
Few precedents exist for reporting biomonitoring data to
individuals when there is little information for interpret-
ing health implications. The first discussion of this issue
was the Department of Health, Education and Welfare's
1979 Belmont Report [35]. The report's guidelines for
protecting human subjects in research rest on four princi-
ples: autonomy, which includes the right-to-know (or the
right-not-to-know) as a basis for self-determination in act-Environmental Health 2009, 8:6 http://www.ehjournal.net/content/8/1/6
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ing on research results; beneficence and non-malfeasance,
which together encompass the researcher's responsibility
to maximize good and minimize harm; and justice, which
refers to the distribution of benefits and harm [35].
"Autonomy" and "justice" weigh in favor of reporting
individual results to study participants. "Beneficence"
encourages researchers to consider benefits, such as
empowering individuals and communities to take actions
to direct their clinical care, reduce hazardous exposures,
protect their health, and participate more fully in public
health research and policy. "Non-malfeasance" considers
the potential for report-back to result in fear, worry,
stigma, or legal and economic complications (related to
health insurance or property values, for example) and the
possible promotion of unnecessary or counter-productive
interventions [30]. Although public health professionals
have developed methods for reporting to individuals on
regulated contaminants such as lead, study participants
often are not informed of their personal results that lack
regulatory or clinical significance. The issue of reporting
individual-specific data to participants has traditionally
been more of a concern in clinical medicine since public
health studies generally have dealt with community-level
data, such as cancer registry information or environmen-
tal contamination data in media such as food and water
[27].
Finally, biomonitoring has implications for environmen-
tal justice. Communities that are socially, economically,
and politically marginalized – from Native American
communities in Akwesasne, New York, and St. Lawrence
Island, Alaska, to African-American communities in Ann-
iston, Alabama, and New Orleans – are beginning to con-
duct biomonitoring research to track exposures (cross-
sectionally and longitudinally), record the extent of com-
munity-specific contamination, and leverage government
funding, industry action, or legal remedies. However,
environmental justice advocates have approached bio-
monitoring with caution because of concerns that "after-
the-fact" measurements cast communities as environmen-
tal hazard detectors [36]. Furthermore, this strategy can
potentially "over-scientize" environmental health prob-
lems, overlooking upstream causes rooted in social ine-
quality, economic exploitation, and racial discrimination
[37,38].
As a powerful and scientifically contested method, eluci-
dating the ethical and policy implications of biomonitor-
ing is critical for providing guidance to those who design
biomonitoring programs and for those faced with the
daunting task of interpreting uncertain data and making
decisions about how to protect health.
Methods
Our interest in this area stems from our own research that
entails environmental sampling of household air and
dust, as well as biomonitoring, to assess the presence of
endocrine-disrupting chemicals potentially linked to
breast cancer [30]. The research partners in this project
have chosen to report aggregate exposure assessment
results through peer-reviewed publications, media out-
reach, and public meetings, and to report individual
results back to study participants. As we developed this
project, we wanted to determine what information on
report-back protocols is currently available to researchers
and communities. This included examining exposure
reports published by government agencies, "best practice"
guidelines issued by professional associations, and jour-
nal articles on individual studies. We also interviewed sci-
entists and community members involved in
biomonitoring research. We specifically assessed how
documents presented exposure data, and what informa-
tion, if any, was provided about interpreting and acting on
the exposure data. We also examined how scientific uncer-
tainty and data gaps were explained to communities and
study participants. We interviewed other scientists doing
exposure studies to see how they decided on report-back
processes. Interview protocols were reviewed and
approved by Brown University's Institutional Review
Board. We began by contacting colleagues who were
involved in academic and advocacy biomonitoring
research, and added to our sample researchers that our
colleagues recommended, through snowball sampling.
Our data come from 26 interviews, a review of relevant lit-
erature, and participant-observation at conferences and
workshops where these report-back issues have been
debated and discussed. Un-cited quotations and informa-
tion come from those interviews and observations.
Results
Frameworks for Communicating Biomonitoring Results
When considering the issue of whether and how to report
individual data to study participants, scientists must
weigh participants' right-to-know and the potential bene-
fits of receiving the information against the possible psy-
chological or financial harm of trying to make sense of
data that may not provide a clear picture of potential
health implications or guidance on how to reduce expo-
sure [25,26]. Our interviews, observations, and assess-
ments of the literature revealed three distinct frameworks
used by scientists for reporting back biomonitoring
results: 1) clinical ethics, a biomedically-driven approach;
2)  community-based participatory research (CBPR); an
approach focused on prevention research and 3) citizen-
science data judo an advocacy-driven approach. The dis-
tinctions between these frameworks are summarized in
Table 1.Environmental Health 2009, 8:6 http://www.ehjournal.net/content/8/1/6
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1) Clinical ethics assumes that decisions about whether
and how to report individual biomonitoring results rests
with scientists and medical experts, and should be based
on whether the risk relationship between exposure and
health effects is understood [39]. For biomarker levels
when an exposure-health outcome relationship is known,
the clinical action level, or "the level at which biomarker
results will be of concern," should be determined prior to
the start of the study [40]. If the results fall below this clin-
ical action level, individual data is generally not reported
to participants. The clinical medicine model gives more
weight to the expert-researcher's role in avoiding possible
harm to study participants from reporting uncertain infor-
mation and less weight to the study participants' ability to
process complex and uncertain scientific information and
respond autonomously. The clinical ethics approach may
preclude precautionary action by participants whose bio-
monitoring results may approach but still be below an
"action level," or regulatory benchmark of concern, even
if the evidence suggests that there are health effects below
the action level, as in case of lead or mercury. Moreover,
the clinical ethics framework offers a narrow view of the
potential for beneficial action – usually focused on medi-
cal intervention or public health interventions based on
regulatory guidelines or a legal mandate (such as child
lead screening). In certain instances, these regulatory
benchmarks are legally or scientifically contested. In prac-
tice, the clinical ethics framework overlooks the signifi-
cant evolution of clinical communications. In particular,
patients have become more proactive in directing their
own health care, often by tracking screening results, such
as blood pressure and cholesterol, even when levels fall
below a clinical action criterion [39,41]. In addition, the
potential for individual-level data to provide relevant
information on an individual's health is further compli-
cated by the possibility of future scientific advancements
in establishing links between exposure and health out-
comes. Indeed, as one academic research scientist inter-
viewed stated:
" [individual results] are part of their medical history, so
potentially in a few years that might be useful information."
Because no health effects are conclusively linked to indi-
vidual low-level exposure for the majority of chemicals
tested in biomonitoring studies, this clinical framework
will likely lead researchers to report data only on an aggre-
gate level. Nevertheless our interviews with three medical
doctors conducting biomonitoring research suggest a
potential shift in the clinical ethics framework. Based on
their experiences as practitioners and researchers they saw
certain advantages of engaging participants openly about
biomonitoring results and their uncertainties to ensure
productive clinical interactions.
Table 1: Frameworks for Communicating Biomonitoring Results
Framework Orientation Right-to-Know 
Emphasis
Communication Strategy Protocol Development
Clinical Ethics Biomedical Weak Individual results communicated if 
exposures reach clinical action levels, 
or if exposure/health outcome 
relationships are understood.
Protocols developed primarily by 
scientific and medical experts.
Participant confidentiality is 
paramount. No opportunities for 
participants to share results with 
each other.
Community-Based 
Participatory 
Research
Prevention Strong, while also 
protecting participants' 
right-not-to-know their 
results.
Encourages communication of 
aggregate and individual-level results 
to study participants with an 
emphasis on explaining scientific 
uncertainties and addressing 
concerns about community 
stigmatization.
Participant right-to-know explained 
at the point of study recruitment and 
consent.
Protocols developed jointly by 
scientific and community partners.
Confidentiality of participants is 
important, although some studies 
may offer opportunities for 
participants to share results with 
each other, if they wish.
Protocols seek to balance 
community-right-to-know with 
individual right-to-know.
Citizen-Science 
Data Judo
Advocacy Strong Encourages report-back of aggregate 
and individual-level results to study 
participant to support precautionary 
individual action, communications, 
and policy change.
Protocols developed by scientific 
experts affiliated with advocacy 
organizations, sometimes with 
consultation from study participants.
Participants encouraged to share 
results with each other and to speak 
publicly about their results to the 
media and broader public.Environmental Health 2009, 8:6 http://www.ehjournal.net/content/8/1/6
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While health-based benchmarks are unavailable for most
of the chemicals tested in humans, population surveil-
lance biomonitoring programs that have emerged over
the last ten years provide useful comparison data for indi-
vidual biomonitoring results. Indeed, scientists involved
in an epidemiological cohort study of the developmental
effects of pesticide exposures explained that the research
team began by only reporting aggregate biomonitoring
results, but subsequently reported individual-level results
because exposure levels could be compared to the
national average levels provided by the CDC's biomoni-
toring information [19]. Although these comparisons are
useful, they often do not help elucidate potential exposure
pathways and sources nor do they relate exposures to lev-
els that have been associated with health effects.
2)  Community-based participatory research (CBPR) is a
framework in which decisions about individual results
communication rest equally between scientists and the
study community. This approach assumes that individual
and aggregate-level reporting of study results can
empower communities and individuals to act on scientific
evidence [42] and can restructure unequal and discrimi-
natory power relationships [43]. The approach stipulates
that the sharing of knowledge (such as biomonitoring
results) between researchers and participants can have an
impact beyond the relevance of the knowledge for indi-
vidual health [44]. Therefore, CBPR encourages as much
information dissemination as possible to study partici-
pants, and posits that ownership of collected data lies pri-
marily with the individual participants from whose
homes or bodies the original samples were taken [42].
A recent article published on reporting pesticide exposure
results to farm worker families in North Carolina echoes
this approach, stating that, "Communicating risk to
affected individuals should be an integral part of any com-
munity-based project. It is ethical to return information to
the owner of that information" [45]. Indeed, investigators
in this farmworker study assumed that individual report-
back for all chemicals analyzed would occur, and there-
fore the main question was not whether to report individ-
ual results, but how. According to this CBPR framework,
even information about an exposure for which a corre-
sponding risk relationship is not available can have some
benefits to participants, such as taking action to reduce
personal exposures. The North Carolina study emphasizes
community involvement in the development of report-
back protocols to address the interests and concerns of
study participants:
In terms of the ambiguity, [the participants] thought it was
important that the scientists present la verdad (the truth).
If this meant telling women that it was not possible to know
the level of danger represented by the findings, they would
prefer to know that rather than to have the scientists give
them a simpler but incomplete answer [45].
Thus, the CBPR approach to reporting data assumes that
results should be disseminated to participants not only to
communicate health information, but also to address dis-
parities in access to knowledge that traditionally charac-
terize 'lay-expert' relationships [46]. The CBPR approach
must be strategic, however, since this framework raises
potential conflicts of community versus individual right-
to-know: the broad dissemination of biomonitoring
results can adversely affect communities under study,
even if the rights and confidentiality of individual study
participants are protected. Indeed, communities exposed
to toxic contaminants with significant health risks, may be
collectively or individually stigmatized. Individually, they
may be denied jobs, health or life insurance if they are
associated with an "at risk" population. Collectively, a
community perceived as "contaminated" may be passed
over for programs or benefits, face stereotyping that affects
the quality of health care, or suffer lost real estate values
or financial liability for remediation [47]. For example, as
early news broke of elevated PCB levels in the community
of Broughton Island in northern Canada, and before the
full extent of contamination was understood to extend
throughout the circumpolar region, Broughton Islanders
were initially shunned as the "PCB people" with an
adverse impact on the livelihood of the fishing commu-
nity [[48], p. 108]. These potential pitfalls of report-back
and right-to-know can be proactively addressed if
researchers purposefully develop protocols and commu-
nication strategies in partnership with study communities
of a biomonitoring project [30,49]. Key to this process is
a collective understanding about who represents the inter-
ests of study communities and how their issues can be
effectively deliberated and incorporated into protocol
development.
3) Citizen science 'data judo,' or what we term "advocacy
biomonitoring," is a strategy in which study design and
individual results communication are shaped primarily
by policy goals to improve chemical regulation. Indeed
this framework assumes that personalized information
about chemical body burden can broaden public support
for toxics use reduction policies, and motivate individuals
to pursue both collective activism and individual expo-
sure reduction. Environmental advocacy groups and com-
munities marshal their own scientific resources and
expertise to conduct research, and report-back strategies
are specifically aimed to advance regulatory and policy
change [50]. Our interviews with scientists who con-
ducted biomonitoring studies for environmental organi-
zations, as well as the individuals who participated,
support this framework.Environmental Health 2009, 8:6 http://www.ehjournal.net/content/8/1/6
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Although the 'data judo' approach to report-back has
overlapping goals with the CBPR framework, there are
some important differences. While CBPR is primarily
research driven and aims to use report-back strategies in
order to break down power and knowledge disparities
between scientists and communities, the data judo
approach is advocacy-driven and explicitly seeks to mobi-
lize constituencies by increasing public awareness about a
specific regulatory issue or policy initiative. Over the past
five years, there has been a proliferation of body burden
studies spearheaded by environmental organizations.
Three milestone activist body burden studies were con-
ducted by the Environmental Working Group (EWG). The
first study, known as the Body Burden Study, recruited nine
volunteers, most of whom were prominent environmen-
tal advocates, to have their blood and urine tested for the
presence of 210 chemicals commonly found in consumer
products and industrial pollution streams [28]. An aver-
age of 91 industrial compounds, pollutants, and other
chemicals were found in the blood and/or urine of the
study participants, with a total of 167 chemicals found in
the entire group. The report on this study appears on the
EWG website where viewers can click on a thumbnail
photo of each study participant to see what contaminants
are in that person's body.
The second EWG study examined the presence of a cate-
gory of brominated flame retardants (PBDEs) in the breast
milk of 20 first-time US mothers [29]. This study found an
average level of bromine-based chemicals in breast milk
that was 75 times the average found in recent European
studies [51,52]. Milk from two study participants con-
tained the highest levels of fire retardants ever reported in
the United States, and milk from several of the mothers in
EWG's study had among the highest levels of these chem-
icals yet detected worldwide. The third study examined
the presence of chemicals commonly used in cosmetics
and body care products in teenaged girls. The study
detected sixteen chemicals from four chemical families –
phthalates, triclosan, parabens, and musks – in blood and
urine samples from twenty participants aged 14–19 years
old. Many of these chemicals are linked to potential
health effects, including cancer and hormone disruption
[53].
Advocacy biomonitoring has made the image of ubiqui-
tous human exposures to chemicals resonate widely in the
media, regulatory, and policy arenas, and has led to a pro-
liferation of studies by several other environmental organ-
izations and media outlets, including Commonweal,
World Wildlife Federation, Greenpeace, Environmental
Defence (Canada), the Sightline Institute, National Geo-
graphic, and a major newspaper in Oakland, California
[15,54-59]. Advocacy biomonitoring highlights the fail-
ure of environmental regulations and policies, such as the
Toxics Substances Control Act (TSCA), to protect the pub-
lic from exposures to ubiquitous contaminants, most of
which have not been tested to assess their potential short-
and long-term health impacts. Many of these studies also
raise questions about whether current regulations are
effective at protecting environmental health. As a result of
extensive public outreach by both organization scientists
and study participants, advocacy biomonitoring has gar-
nered substantial regulatory attention, and legitimated
mounting public concern about the ubiquitous presence
of these chemicals in consumer products and diverse envi-
ronments [60]. With few exceptions, these advocacy stud-
ies report data to study participants individually and also
provide opportunities for them to talk publicly about
their results. For example, EWG provides online personal
biographies of study participants in their Body Burden
and Breast Milk studies [28,29,61]. Many of these biogra-
phies emphasize participants' efforts to lead 'healthy life-
styles' and the fact that they did not work directly with
chemicals in their jobs or live near major pollution
sources. Participants in advocacy biomonitoring studies
savored the opportunity to share their results with other
study participants to better contextualize their meaning
and highlight opportunities for exposure reduction. As
one participant noted:
...the important thing, I think, to me, was understanding
my results in the context of other people's results. So that
while each of us got our results individually... it was only
sort of when most of us [study participants] agreed to be in
a conference call together to talk about it that I sort of began
to understand what my own results meant, and how I felt
about it in the context of other people's reactions... And so
it was very important to me that as a group we agreed to
share our results. Not that we now know exactly what it
means, but it was interesting to note that the biggest fish
eaters had the highest levels of mercury.
One of the more controversial aspects of advocacy bio-
monitoring is that it explicitly challenges traditional Insti-
tutional Review Board (IRB) protocols of protecting
participant confidentiality, by giving study participants
opportunities to discuss their results publicly, with the
media and each other. Based on our interviews with aca-
demic scientists, many IRBs have traditionally allowed
aggregate reporting of study results, while restricting or
strongly discouraging the conveyance of individual-level
information. For example, some academic IRBs require
passive individual report-back protocols, which prohibit
researchers from asking participants if they want to receive
results. Although IRB concern about participant confiden-
tiality is warranted, report-back protocols that require
greater initiative on the part of study participants to
acquire their results ignores the fact that many individuals
want their own data in order to take individual or collec-Environmental Health 2009, 8:6 http://www.ehjournal.net/content/8/1/6
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tive action to reduce exposures. Participants may also
want to share their personal results with other study par-
ticipants or collectively through their own networks, com-
munities, and public forums. As one scientist from an
advocacy organization argued:
I think part of the challenge for all of the biomonitoring
studies that are going on, including ours, is that you want
to do it by the book, so that you write up an IRB [protocol]
like any other study with human subjects, but in a way,
doing it by the book is exactly what this is not about.
Therefore, some advocacy biomonitoring studies have
encouraged IRBs to examine how traditional standards of
confidentiality may impose problematic restrictions on
individual results communication. For some communi-
ties, these restrictions can be perceived as undermining
the capacity of study participants to understand the impli-
cations of the study and to take protective action by first
comparing their individual results in the context of those
of their peers.
The above analysis of these three approaches to biomoni-
toring results communication also elucidated some gen-
eral guidelines for reporting exposure data to study
participants.
Central Issues in Reporting Exposure Data to Individuals 
and Communities
1) Providing background information to make individual results 
meaningful
Several scientists and participants recommended compar-
ing individual data with aggregate study results. Such
comparisons are useful for placing the information into a
familiar context. As Quandt et al. found: "presenting indi-
vidual exposure data with reference to actual community
data, rather than more abstract population-level reference
data, engages community members' interest." [45]. The
use of comparisons is also recognized in the literature on
risk communication as important when the values being
communicated appear small, or when risks are unfamiliar
to the involved community [62]. Body burden studies can
fit both of these criteria: chemicals are often detected in
seemingly low concentrations and they may involve
chemicals unfamiliar to the general population.
Another system for reporting individual-level data is to
compare it with other published studies, such as the CDC
reports [17,19,20], when such studies exist. It is important
to keep in mind, however, that there can be some confu-
sion about what this comparison implies. For example,
one researcher indicated that when pesticide exposure
results were reported to individuals, it was critical to
ensure that any comparisons to general population levels
from the CDC report were not misinterpreted as safety
benchmarks. In this way, the exposure distribution for the
population often stands in as a substitute 'population
norm' [40,45]. This can have two potential negative
effects on the participants' understanding of their risk: (1)
it can lead to a false sense of security, with participants
who have exposure levels at or below a community aver-
age and (2) it can lead to unnecessary concern when those
with higher exposure levels than the study average assume
that they have unsafe levels, regardless of the fact that the
entire cohort might have exposures that are significantly
below levels that indicate cause for concern. One scientist
we interviewed, who directed an exposure study on bro-
minated flame retardants, indicated that two study partic-
ipants had extremely high levels of PBDEs in their tissue
samples. This caused at least one participant to be con-
cerned, although currently there are no human health
studies to indicate whether or not her results posed health
risks for her or her child:
The participant who had the second-highest result was
really pretty blown away by it. She had done the study
expecting that she would be one of the more healthy, safe,
you know, protected... It's really an unfortunate part about
enrolling [participants] in studies and giving them results
about contaminant levels in their bodies when you don't
have an even distribution or a way that would kind of pre-
dict or prepare them for where they might be in that distri-
bution and she took it really hard ... the rest of the ...
[participants] felt lucky and felt protected.
It is clear that using study or population exposure distri-
butions as a way to interpret individual-level data has
potential pitfalls. However, this fact should not prevent
exposure distributions from being reported in the context
of individual-level results. Instead, care should be taken to
ensure that study participants understand that population
averages should not be considered safety benchmarks.
Whenever possible, information about comparison meas-
ures in other populations should be coupled with an
explanation of the potential health implications of these
levels and appropriate regulatory benchmarks.
2) Developing report-back protocols and contention among 
researchers regarding individual versus aggregate communication of 
results
Our interviews revealed that the process for developing
report-back protocols varies widely, both among aca-
demic and advocacy biomonitoring studies. Some
researchers develop report-back protocols with little com-
munity input, while others solicit input from the study
community, scientific colleagues not directly involved in
the study, and social scientists. Most interviewees
acknowledged the importance of having community rep-
resentatives involved in the decision of whether and how
to report individual and aggregate study results. They feltEnvironmental Health 2009, 8:6 http://www.ehjournal.net/content/8/1/6
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that it should be the community's decision whether indi-
viduals receive their own data, especially in situations
when studies included participants whose illness was
potentially linked to a substance under study. Neverthe-
less, for academic studies or research involving commu-
nity-academic collaborations, this sentiment must
contend with the fact that all entities that receive federal
funding for research must operate in accordance with fed-
erally prescribed IRB procedures; this makes IRBs the final
arbiters of whether or not to approve individual-level
notification of study participants about biomonitoring
results. The academic scientists we interviewed reported a
wide variation in the willingness of their IRBs to grapple
with the bureaucratic and logistical challenges of review-
ing and approving individual-level report-back protocols
for biomonitoring studies. In addition, some described a
lack of consensus among study collaborators, including
academic scientists and members of community advisory
panels, about whether to report individual data. The disa-
greements over how to design report-back protocols show
that, even when there is a commitment to right-to-know
and community-based research, deciding how to report to
individuals in biomonitoring and exposure assessment
studies may not be simple to negotiate among collabora-
tors. For example, physicians sitting on an advisory board
for one biomonitoring study tended to discourage indi-
vidual report-back due to concerns that patients may have
health-related questions linked to their study results that
most doctors could not realistically answer. Conversely,
community advocates and some industry representatives
tended to favor releasing individual results to study partic-
ipants, viewing this as a right-to-know issue.
3) Factors affecting how results are reported
Most scientists described a system of individual and aggre-
gate report-back that involved a combination of written
materials and conversations with experts, either over the
phone or in person. Some had a form of passive reporting,
where study participants could contact researchers if they
wanted to confidentially receive their personal results.
This system also gives participants the opportunity to opt
out of receiving their individual-level information.
Another researcher stressed the need to follow up report-
back with support from a counselor and/or to have some-
one participants can contact down the line when ques-
tions arise related to emerging health issues or new
concerns. One scientist discussed the need to remain
extremely flexible and available for participants, since a
third of the participants who did not opt to call in for
results later expressed interest in getting their results dur-
ing a follow-up survey a few weeks later. This suggests that
passive reporting may not be sufficient for providing
results to participants who want them.
The report-back process offers the potential to use aggre-
gate and individual-level information to develop expo-
sure reduction interventions. Indeed, receiving
information about how to remove pesticides from the
home or how to prevent future contamination was
reported by participants to be the most important part of
the report-back process in two pesticide exposure studies.
The promotion of public health interventions directly
related to study results helps scientists ensure that the
information provided to participants has a positive effect
on their ability to take action to promote health and well-
being [63]. One scientist brought up the importance of
reporting individual study results in combination with
specific exposure reduction recommendations that partic-
ipants can follow individually:
The most important component of that for us was not only
giving the information but giving information about what
the women could do. So that reporting back is always linked
to action, so that they are not getting the information with-
out having any idea of what they can do about it.
In one pesticide study, the health workers explained direct
actions that all women could take to prevent pesticides
from entering their homes and getting picked up by chil-
dren, including closing windows during crop-spraying,
and having farm workers change clothes before entering
the home. In addition, brochures were provided, with
information in Spanish about storing and washing work
clothes separately and the idea of pesticide residues being
invisible [40,45]. Other biomonitoring studies of persist-
ent organic pollutants that bioaccumulate up the food
chain provide participants with information about how to
reduce their consumption of animal products or decrease
the presence of contaminants in household dust by
switching to less toxic consumer products. However, sci-
entists are often forced to balance the potential disruption
and cost of an intervention with the strength of the infor-
mation indicating a pollutant's origins and health impacts
[30]. For example, one scientist leading a study on bromi-
nated flame retardants indicated that he would provide
participants information on how to reduce levels of ani-
mal fat in their diet, citing other health benefits associated
with this action. On the other hand, he also indicated that
he would refrain from advising participants to take more
costly or inconvenient action to minimize the presence of
PBDEs in household dust. This is especially true if the
effectiveness of these interventions has not been assessed:
Right now my gut feeling would be not to tell people you
should throw away all your furniture and buy all new fur-
niture. That seems kind of extreme, right?
Thus, it seems that in the case of PBDEs, for which the
health effects are less well understood, the decision ofEnvironmental Health 2009, 8:6 http://www.ehjournal.net/content/8/1/6
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whether or not to provide suggestions for exposure reduc-
tion involved balancing the level of confidence in the effi-
cacy of the possible intervention with the disruption that
the intervention would cause, and whether or not the
intervention has other public health benefits besides min-
imizing pollutant exposures, such as reducing animal fat
content in the diet, which can reduce the risk of heart dis-
ease.
Some biomonitoring results raise conflicts with an exist-
ing public health practice with a known health benefit, as
with breastfeeding. While there are indications that
PBDEs may have potential developmental health effects
on offspring, toxicological evidence suggests that most of
these effects occur in utero rather than through exposures
through breastfeeding [14]. However, breast milk studies
have been controversial because of concerns that they may
discourage breastfeeding, despite its known health bene-
fits. A recent survey of breastfeeding women suggests that
learning about the presence of chemicals in their breast
milk may lead them to wean earlier than intended [64],
although the survey for this study was hypothetical and
did not actually measure whether in fact reporting moni-
toring results actually changed the duration of breastfeed-
ing. Although further research is needed to examine
whether in fact reporting biomonitoring results actually
changes breastfeeding behaviors, this issue remains con-
troversial among public health advocates. To respond to
this debate, a recent article proposed a model informed
consent protocol for breast milk biomonitoring studies
that includes "advice that breastfeeding is almost always
considered to be the best form of nutrition for a baby, and
that the fact that the study is being carried out should in
no way be taken as implying anything to the contrary"
[65]. All three scientists we interviewed who were
involved in breast milk studies reported that they encour-
aged participants to breastfeed. Empirical investigation of
mothers' responses in breast milk studies that encourage
breastfeeding could inform the design of future monitor-
ing efforts.
Finally, debates over "risk messaging" related to biomon-
itoring research are most difficult when health implica-
tions warrant exposure-reduction, but interventions are
either impossible, unjust, or would produce more delete-
rious consequences. In the 1980s and early 1990s, com-
munication of biomonitoring results among Arctic Inuit
communities called into question the consumption of
their traditional food source of large marine mammals.
Contaminants bioaccumulate and are delivered through
many marine mammal food sources that are essential to
community survival, subsistence and hunting culture. In
this context, the conundrum lies in the paucity of viable
alternative foods sources. Imported, market-based foods
pose their own, arguably more dire health consequences
in the form of malnutrition, obesity, cardiovascular dis-
ease and diabetes [49,66]. Increasingly, messages encour-
age consumption of particular species with lower
contaminant levels or specific cuts of flesh. Yet, mounting
evidence of the reproductive, immunological, and devel-
opmental effects of these persistent contaminants leave
many communities and scientists in an uncertain situa-
tion in terms of report-back strategies [49]. Scientists and
community members involved in these studies support
community right-to-know; however, this work also poses
a significant challenge since exposure reduction strategies
are extremely difficult to employ. In the case of the Inuit,
efforts to reduce pollutant levels in marine mammals
require international political action and a long time hori-
zon, given the environmental persistence of some con-
taminants [66,67].
4) Addressing varying levels of literacy
Biomonitoring studies involve populations with varying
levels of literacy [68,69]. In some cases, as with the EWG
breast milk study, participants are pooled from popula-
tions of environmental activists who already have high
levels of environmental health literacy. One academic sci-
entist we interviewed who was conducting breast milk
biomonitoring, noted that participants came from two
distinct groups, one that was upper middle class with a
post-graduate level of education, and another that was
working class, with a high school or lower level of educa-
tional attainment. The latter group was far less inclined to
seek their biomonitoring results. However, participants
who are members of marginalized groups with low levels
of scientific literacy may be eager to hear their results with
a preference to have materials read to them and be shown
diagrams, graphs and pictures to interpret data [45].
Another scientist involved in a cohort study on pesticides
in low-income urban women and children provided fur-
ther evidence that populations of low literacy are inter-
ested and can demonstrate a high level of comprehension
in interpreting individual results:
Yeah, the research workers have been getting the same
questions that they've been getting for years now, you know,
when are we going to get our individual results for our kids?
You know when are we going to know about pesticides?
When are we going to know the results from our [monitor-
ing] ...?
Thus, successfully conveying complex results to popula-
tions with low levels of scientific literacy requires carefully
crafting report-back protocols so that participants are
engaged and able to understand the material presented to
them. It is also necessary to communicate with members
of the participant community during the creation of
report-back materials, to ensure that the information isEnvironmental Health 2009, 8:6 http://www.ehjournal.net/content/8/1/6
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relevant to their life experiences. If these measures are suc-
cessfully undertaken, our interviews with researchers sug-
gest that populations with lower levels of scientific literacy
are as interested in receiving their individual data as more
educated groups are. Ultimately, a participant's decision
about receiving individual results is a personal one, and
researchers must ensure that participants can make a clear,
deliberative choice regarding their right-to-know or not-
to-know.
5) IRB requirements, standards of confidentiality, and individual-
report-back
Although IRBs focus on protecting the rights and confi-
dentiality of individuals, this may not require that indi-
vidual results be reported back to study subjects. In fact,
under certain circumstances, IRBs may discourage individ-
ual report-back. The scientists we interviewed faced a
range of responses from IRBs to their report-back proto-
cols. One researcher recounted how the IRB initially
opposed releasing individual study results to participants.
However, he was able to convince IRB members to recon-
sider their decision by demonstrating that community
representatives on the study's advisory board supported
the report-back protocol. Another IRB limited researchers
to calling participants and referring to them by their indi-
vidual code number, rather than their names in order to
protect confidentiality. Conversely, environmental advo-
cacy organizations that conducted studies gave partici-
pants numerous opportunities to discuss their individual
results with each other. In one study we examined, confer-
ence calls were held for all participants before and after
results were disseminated and participants were encour-
aged to share their personal response to receiving their
results with the group. The benefit to participants was that
this process enabled them to share thoughts regarding
pollutant sources and ways to reduce exposures. This
approach encourages a reevaluation of traditional proto-
cols aimed at protecting participant confidentiality and
suggests new ways for researchers to enhance the partici-
patory nature of disseminating and interpreting biomon-
itoring results. An IRB's duty to protect confidentiality
ensures that personal information is not released without
a participant's explicit desire and instruction. Neverthe-
less, as with any health information, a person should be
free to share their information with others, as long as they
do not consciously violate other people's desire to not
share their data.
Discussion
Biomonitoring provides new techniques and innovation
in environmental health science for detecting and under-
standing the health implications of chemical trespass in
people's bodies. Some biomonitoring projects are done
by academic, government, and regulatory institutions and
involve varying degrees of lay involvement. Others are
done by environmental health advocacy organizations in
order to mobilize the public and lobby relevant officials
and legislators for regulatory and policy change. Biomon-
itoring also raises new ethical challenges that require
democratizing the research enterprise to allow study par-
ticipants to play a larger role in interpreting, disseminat-
ing and leveraging study results to take action.
A consensus has yet to emerge regarding the ethics of
reporting individual data on environmental exposures
when the relationship between exposures and health out-
comes is not established [70]. Indeed, some environmen-
tal health advocates and scientists who generally support
the notion of community right-to-know remain wary of
individual notification of data when the clinical implica-
tions are uncertain. For example, recent studies on the
presence of PBDEs, PCBs, and other toxins in breast milk
have raised some controversy about how to report bio-
monitoring results in light of the many known benefits of
breastfeeding [71]. Nevertheless, participatory research
models are spilling over into the environmental health
arena, compelling more scientists and advocacy organiza-
tions to think through the issue of whether and how to
provide individual-level biomonitoring information
[30,45]. The literature and our interviews with scientists
and study participants conducted for this study, although
not unequivocal, indicate a trend in favor of addressing
report-back strategies in the recruitment and consent
process for research studies. Our research suggests that the
ethical issues of reporting back exposure monitoring
results necessitates addressing the rights of study partici-
pants to information before, during, and after studies so
that they can make informed decisions and be empow-
ered to take action. Study participants often want their
individual results and an interpretation of them in terms
of what potential exposures may mean for their health or
opportunities to reduce exposure. However, researchers
and public health practitioners face ethical issues in inter-
preting exposure results when health and safety data are
not available for the pollutants under study or when there
is no scientific consensus about the risks associated with
exposures or efficacy of exposure reduction strategies.
Perhaps the most important issue to emerge from our
interviews with academics, scientists from advocacy
organizations, and study participants is that it is desirable
to set expectations for any exposure assessment or bio-
monitoring study before commencing data collection and
setting up results communication protocols. One impor-
tant aspect of this effort is to clarify the inherent scientific
limitations of interpreting what the data collected could
mean for community and individual-level health. Equally
important, even if health implications are unknown, indi-
vidual-level report-back can provide an impetus for peo-
ple to take individual action that could reduce theirEnvironmental Health 2009, 8:6 http://www.ehjournal.net/content/8/1/6
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exposures. It can also provide participants with opportu-
nities to collectively leverage results to support advocacy
that promotes broader biomonitoring efforts to fully
understand population variability in exposures, or inter-
ventions that promote more protective regulation or tox-
ics use reduction.
Conclusion
Much of the new biomonitoring work involves informing
individuals of their chemical exposures, and the prolifera-
tion of individual report-back approaches discussed here
represents a departure from traditional models of report-
ing aggregate study results in ways that are limited to aca-
demic settings, such as professional meetings and peer-
reviewed publications. Of note is the increased effort
among scientists to report chemical exposures whose clin-
ical significance may not be fully known. There is a need
for guidance on the ethical responsibilities associated
with communicating individual and community-level
data. Our research suggests that much of this guidance
cannot solely come from the established arbiters of clini-
cal and research practice, nor from government health
officials, but must also include communities engaged in
research collaboratives that have developed new stand-
ards of ethical report-back and participatory science prac-
tice.
Abbreviations
CDC: Centers for Disease Control; NIOSH: National Insti-
tute of Occupational Safety and Health; EPA: Environ-
mental Protection Agency; PBDEs: polybrominated
diphenyl ethers; PFOA: perfluoroctanoate; PCBs: poly-
chlorinated biphenyls; CBPR: community-based partici-
patory research; EWG: Environmental Working Group;
U.S: United States; IRB: Institutional Review Board.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
RMF, JGB, PB, and RAR originated the research to explore
individual report-back in exposure studies. RMF con-
ceived, designed, and implemented this study, led the
writing, conducted some of the interviews, and analyzed
interviews. JGB helped with the study design, analysis of
interviews, and drafting of the manuscript. PB designed
and implemented the study, analyzed interviews, and
assisted with writing. RGA conducted most of the inter-
views, and participated in revisions of the manuscript.
RAR assisted with analysis of the interviews and partici-
pated with the writing. CP assisted with interviews and
provided critical input on the manuscript.
Acknowledgements
This research is supported by grants from the National Institute of Environ-
mental Health Sciences (1 R25 ES013258-01), the National Science Foun-
dation (SES-0450837 and SES-0822724), the National Heart, Blood, and 
Lung Institute (T15 HL069792), and the UC Berkeley Center for Environ-
mental Public Health Tracking, Cooperative Agreement Number U50/
CCU922409 with the Centers for Disease Control and Prevention. Thanks 
to Maggie Frye for conducting interviews, and to Alison Cohen and Ruth 
Simpson for their valuable editorial assistance on this manuscript. Thanks 
to Crystal Adams, Alissa Cordner, Elizabeth Hoover, Mercedes Lyson, and 
Laura Senier for helpful comments on the manuscript.
References
1. Sarker P: Worried locals seek blood testing: Richmond neigh-
bors fear toxic contaminants.  San Francisco Chronicle. San Fran-
cisco 2000:A20.
2. Doyle J: Trespass Against Us: Dow Chemical and the Toxic
Century.  Monroe, ME: Common Courage Press/Environmental
Health Fund; 2004. 
3. Pausentbach D, Galbraith D: Biomonitoring: is body burden rel-
evant to public health?  Regul Toxicol Pharmacol 2006, 44:249-261.
4. Sexton K, Needham L, Pirkle J: Human biomonitoring of envi-
ronmental chemicals: measuring chemicals in human tissues
is the "gold standard" for assessing exposure to pollution.  Am
Sci 2004, 92:38-41.
5. DeCaprio A: Biomarkers: coming of age for environmental
health and risk assessment.  Environ Sci Technol 1997,
31:1837-1848.
6. Morello-Frosch R: The politics of reproductive hazards in the
workplace: class, gender, and the history of occupational
lead exposure.  Int J Health Serv 1997, 27:501-521.
7. Jackson R, Locke P, Pirkle J, Thompson F, Sussman D: Will biomon-
itoring change the way we regulate toxic chemicals?  J Law
Med Ethics 2002, 30:177-183.
8. Greene A, Morello-Frosch R, Shenassa ED: Inadequate prenatal
care and elevated blood lead levels among children born in
Providence, Rhode Island: a population-based study.  Public
Health Rep 2006, 121:729-736.
9. National Academy of Sciences: Human Biomonitoring for Environmental
Chemicals. Washington, DC 2006.
10. Lioy PJ, Freeman NC, Millette JR: Dust: a metric for use in resi-
dential and building exposure assessment and source charac-
terization.  Environ Health Perspect 2002, 110:969-983.
11. Rudel RA, Camann DE, Spengler JD, Korn LR, Brody JG: Phthalates,
alkylphenols, pesticides, polybrominated diphenyl ethers,
and other endocrine-disrupting compounds in indoor air and
dust.  Environ Sci Technol 2003, 37:4543-4553.
12. Goldstein BD: Advances in risk assessment and communica-
tion.  Annu Rev Public Health 2005, 26:141-163.
13. Metcalf SW, Orloff KG: Biomarkers of exposure in community
settings.  J Toxicol Environ Health A 2004, 67:715-726.
14. Hooper K, She J: Lessons from the polybrominated diphenyl
ethers (PBDEs): precautionary principle, primary preven-
tion, and the value of community-based body-burden moni-
toring using breast milk.  Environ Health Perspect 2003,
111:109-114.
15. Fischer D: What's in You?  Oakland Tribune. Oakland, CA 2005.
16. Whyatt RM, Rauh V, Barr DB, Camann DE, Andrews HF, Garfinkel R,
Hoepner LA, Diaz D, Dietrich J, Reyes A, et al.: Prenatal insecticide
exposures and birth weight and length among an urban
minority cohort.  Environ Health Perspect 2004, 112:1125-1132.
17. Center for Disease Control and Prevention: The First National Report
on Human Exposure to Environmental Chemicals. Atlanta 1999.
18. Vastag B: CDC unveils first report on toxins in people.  JAMA
2001, 285:1827-1828.
19. Center for Disease Control and Prevention: Third National Report on
Human Exposure to Environmental Chemicals. Atlanta 2005.
20. Center for Disease Control and Prevention: Second National Report on
Human Exposure to Environmental Chemicals. Atlanta 2003.
21. California, Senate: California Environmental Contaminant Bio-
monitoring Program.  In SB 1379 Sacramento: OSP; 2006. 
22. Davis DL, Webster P: The social context of science: cancer and
the environment.  Ann Am Acad Pol Soc Sci 2002, 584:13.
23. Wagner WE: Choosing ignorance in the manufacture of toxic
products.  Cornell Law Rev 1997, 82:773-855.Environmental Health 2009, 8:6 http://www.ehjournal.net/content/8/1/6
Page 13 of 13
(page number not for citation purposes)
24. American Conference of Governmental Industrial Hygienists
(ACGIH): TLVs and BEIs based on the documentation of the threshold limit
values and biological exposure indices Cincinnati, OH; 2005. 
25. Schulte PA: The epidemiologic basis for the notification of sub-
jects of cohort studies.  Am J Epidemiol 1985, 121:351-361.
26. Jonsen AR: Ethical considerations and responsibilities when
communicating health risk information.  J Clin Epidemiol 1991,
44:69S-72S.
27. Schulte P, Singal M: Ethical issues in the interaction with sub-
jects and disclosure of results.  In Ethics and Epidemiology Edited
by: Coughlin S, Beauchamp T. New York: Oxford University Press;
1996:178-198. 
28. Body Burden: The Pollution in People   [http://archive.ewg.org/
reports/bodyburden1/]
29. Mother's Milk   [http://www.ewg.org/reports/mothersmilk]
30. Brody JG, Morello-Frosch R, Brown P, Rudel RA, Altman RG, Frye M,
Osimo CA, Perez C, Seryak LM: Improving disclosure and con-
sent: "Is it safe?": new ethics for reporting personal expo-
sures to environmental chemicals.  Am J Public Health 2007,
97:1547-1554.
31. Harris JS: Toxic waste uproar: a community history.  J Public
Health Policy 1983, 4:181-201.
32. Schulte PA, Singal M: Interpretation and communication of the
results of medical field investigations.  J Occup Med 1989,
31:589-594.
33. Stokstad E: Pollution gets personal.  Science 2004, 304:1892-1894.
34. Needham L, et al.: Exposure assessment in the National Chil-
dren's Study: introduction.  Environ Health Perspect 2005,
113:1076-1082.
35. National Institutes of Health: The Belmont Report: Ethical Principles and
Guidelines for the Protection of Human Subjects of Research Bethesda,
MD; 1979. 
36. Bhatia R, Brenner B, Salgado B, Shumasunder B, Prakash S: Biomon-
itoring: what communities must know.  Race, Poverty and Envi-
ronment 2005, 11:56.
37. Morello-Frosch R, Zavestoski S, Brown P, McCormick S, Mayer B,
Gasior R: Social movements in health: responses to and shap-
ers of a changed medical world.  In The New Political Sociology of
Science: Institutions, Networks, and Power Edited by: Kelly Moore, Scott
Frickel e. Madison. WI: University of Wisconsin Press; 2006. 
38. Sze J, Prakash S: Human genetics, environment, and communi-
ties of color: ethical and social implications.  Environ Health Per-
spect 2004, 112:740-745.
39. Shalowitz D, Miller F: Disclosing individual results of clinical
research implications of respect for participants.  JAMA 2005,
294:737-740.
40. Deck W, Kosatsky T: Communicating their individual results
to participants in an environmental exposure study: insights
from clinical ethics.  Environ Res 1999, 80:S223-S229.
41. Bury M: Researching patient-professional interactions.  J
Health Serv Res Policy 2004, 9(Suppl 1):48-54.
42. Bishop R: Initiating empowering research?  N Z J Educ Stud 1994,
29:175-188.
43. Wallerstein N, Duran B: The conceptual, historical, and prac-
tice roots of community based participatory research and
related participatory traditions.  In Community Based Participatory
Research for Health Edited by: Minkler M, Wallerstein N. San Fran-
cisco, CA: Jossey-Bass; 2003:27-52. 
44. Foucault M: Power/Knowledge: Selected Interviews and
Other Writings, 1972–1977.  New York, N.Y.: Pantheon Books;
1980. 
45. Quandt SA, Doran AM, Rao P, Hoppin JA, Snively BM, Arcury TA:
Reporting pesticide assessment results to farmworker fami-
lies: development, implementation, and evaluation of a risk
communication strategy.  Environ Health Perspect 2004,
112:636-642.
46. Sullivan M, Kone A, Senturia KD, Chrisman NJ, Ciske SJ, Krieger JW:
Researcher and researched–community perspectives:
toward bridging the gap.  Health Educ Behav 2001, 28:130-149.
47. Weijer C: Protecting communities in research: philosophical
and pragmatic challenges.  Camb Q Healthc Ethics 1999,
8:501-513.
48. Colborn T, Dumanoski D, Myers JP: Our Stolen Future.  New
York: Penguin; 1996. 
49. Cone M: Silent Snow.  New York: Grove Press; 2005. 
50. Morello-Frosch R, Pastor M, Sadd J, Porras C, Prichard M: Citizens,
science, and data judo: leveraging community-based partici-
patory research to build a regional collaborative for environ-
mental justice in southern california.  In Methods for Conducting
Community-Based Participatory Research in Public Health Edited by: Bar-
bara Israel EE, Amy Shultz, Edith Parker. San Francisco: Jossey-Bass
Press; 2005. 
51. Norén K, Meironyté D: Certain organochlorine and organobro-
mine contaminates in Swedish human milk in perspective of
past 20–30 years.  Chemosphere 2000, 40:1111-1123.
52. Strandman T, Koistinen J, Vartiainen T: Polybrominated diphenyl
ethers (PBDEs) in placenta and human milk.  Organohalogen
Compounds 2000, 47:61-64.
53. Teen Girls' Body Burden of Hormone-Altering Cosmetics
Chemicals   [http://www.ewg.org/book/export/html/26953]
54. Is It In Us: Toxic trespass, Regulatory Failure & Opportuni-
ties for Action   [http://isitinus.org/project.php]
55. Toxic People: The Pollution Within   [http://www7.nationalgeo
graphic.com/ngm/0610/feature4/]
56. Toxic Nation: A Report on Pollution in Canadians
[http:www.environmentaldefence.ca/toxicnation/resources/publica
tions.htm]
57. A Present for Life: Hazardous chemicals in umbilical cord
blood   [http://www.greenpeace.org/international/press/reports/
umbilicalcordreport]
58. Flame Retardants in the Bodies of Pacific Northwest Resi-
dents: A Study of Toxic Body Burdens   [ h t t p : / / w w w . s i g h t
line.org]
59. Bad Blood? A Survey of Chemicals in the Blood of European
Ministers   [http://assets.panda.org/downloads/
badbloodoctober2004.pdf]
60. Iles A: Identifying environmental health risks in consumer
products: non-governmental organizations and civic episte-
mologies.  Public Understand Sci 2007, 16:371-391.
61. Body Burden: The Pollution in Newborns   [ h t t p : / /
archive.ewg.org/reports/bodyburden2/execsumm.php]
62. Williams PR: Health risk communication using comparative
risk analyses.  J Expo Anal Environ Epidemiol 2004, 14:498-515.
63. Altman R, Morello-Frosch R, Brody JG, Rudel R, Brown P, Averick M:
Pollution comes home and gets personal: women's experi-
ence of household chemical exposure.  J Health Soc Behav 2008,
49(4):417-435.
64. Geraghty S, Khoury J, Morrow A, Lanphear B: Reporting individual
test results of environmental chemicals in breastmilk: poten-
tial for premature weaning.  Breastfeeding Medicine 2008,
3(4):207-213.
65. Bates MN, Selevan SG, Ellerbee SM, Gartner LM: Reporting needs
for studies of environmental chemicals in human milk.  J Tox-
icol Environ Health A 2002, 65:1867-1879.
66. Frugal C, Kalhok S, Loring E, Smith S: Knowledge in Action: Cana-
dian Arctic Contaminants Assessment Report II.  Ott a w a ,
Canada: Minister of Indian Affairs and Northern Development; 2003. 
67. Inuit Tapiriit Kanatami: Communicating about Contaminants in Country
Foods: The Experience of Aboriginal Communities Ottawa, Canada; 1995. 
68. Measuring Chemicals in People–What Would You Say? A
Boston Consensus Conference on Biomonitoring   [http://
www.biomonitoring06.org]
69. Nelson J, Scammell M, Altman R, Webster T, Ozonoff D: A new spin
on research translation: the Boston consensus conference on
human biomonitoring.  Environ Health Perspect  in press.
70. Keune H, Morrens B, Loots I: Risk communication and human
biomonitoring: which practical lessons from the Belgian
experience are of use for the EU perspective?  Environ Health
2008, 7(Suppl 1):S1-11.
71. Arendt M: Communicating human biomonitoring results to
ensure policy coherence with public health recommenda-
tions: analysing breastmilk whilst protecting, promoting and
supporting breastfeeding.  Environ Health 2008, 7(Suppl 1):S6.